Open Collections

UBC Faculty Research and Publications

Drugs for Overactive Bladder Symptoms Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 57 reviews drugs for overactive bladder symptoms. Conclusions: Oxybutynin and tolterodine (all forms) have not been tested in randomized controlled trials (RCTs) beyond 12 weeks nor in elderly patients or those with serious co-morbidities. Oral anticholinergic formulations and regimens are equivalent in benefit; evidence for transdermal oxybutynin is less clear. Symptomatic benefit occurs in 60% of people with OAB treated with an anticholinergic drug versus 45% of people treated with placebo, ARR 15%, NNT 6 to 7. Anticholinergic side effects, particularly dry mouth, are frequent: ARI 22%, NNH 4 to 5. The benefit of anticholinergic drugs (0.6 less leakage episodes per day) must be weighed against the harm (3% of patients treated for 12 weeks experienced a serious adverse event).

Item Metadata

Title
Drugs for Overactive Bladder Symptoms
Alternate Title
Therapeutics Letter 57
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2005-12
Description
Therapeutics Letter 57 reviews drugs for overactive bladder symptoms. Conclusions: Oxybutynin and tolterodine (all forms) have not been tested in randomized controlled trials (RCTs) beyond 12 weeks nor in elderly patients or those with serious co-morbidities. Oral anticholinergic formulations and regimens are equivalent in benefit; evidence for transdermal oxybutynin is less clear. Symptomatic benefit occurs in 60% of people with OAB treated with an anticholinergic drug versus 45% of people treated with placebo, ARR 15%, NNT 6 to 7. Anticholinergic side effects, particularly dry mouth, are frequent: ARI 22%, NNH 4 to 5. The benefit of anticholinergic drugs (0.6 less leakage episodes per day) must be weighed against the harm (3% of patients treated for 12 weeks experienced a serious adverse event).
Subject
Aged; Cholinergic Antagonists; Morbidity; Oxybutynin; Tolterodine Tartrate; Urinary Bladder, Overactive
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433636
URI
http://hdl.handle.net/2429/85046
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International